Skip Navigation



Human Molecular Genetics Advance Access published online on March 30, 2007

Human Molecular Genetics, doi:10.1093/hmg/ddm060
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
16/9/1113    most recent
ddm060v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mosig, R. A.
Right arrow Articles by Martignetti, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mosig, R. A.
Right arrow Articles by Martignetti, J. A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Loss of MMP-2 disrupts skeletal and craniofacial development, and results in decreased bone mineralization, joint erosion, and defects in osteoblast and osteoclast growth

Rebecca A. Mosig1, Oonagh Dowling1, Analisa DiFeo1, Maria Celeste M. Ramirez1, Ian C. Parker1, Etsuko Abe2,3, Janane Diouri4, Aida Al Aqeel5, James D. Wylie6, Samantha A. Oblander6,{dagger}, Joseph Madri7, Paolo Bianco8, Suneel S. Apte6, Mone Zaidi2,3, Stephen B. Doty4, Robert J. Majeska9, Mitchell B. Schaffler9 and John A. Martignetti1,10,11,*

1 Departments of Human Genetics, Mount Sinai School of Medicine, New York, NY 10029, USA 2 Departments of Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029, USA 3 Departments of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA 4 Mineralized Tissue Laboratory, Hospital for Special Surgery, New York, NY 10021, USA 5 Riyadh Armed Forces Hospital, Riyadh, Kingdom of Saudi Arabia 6 Department of Biomedical Engineering and Orthopedic Research Center, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA 7 Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06520, USA 8 Department of Experimental Medicine and Pathology, La Sapienza University, Rome, Italy 9 Departments of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA 10 Departments of Pediatrics, Mount Sinai School of Medicine, New York, NY 10029, USA 11 Departments of Orthopedics, Mount Sinai School of Medicine, New York, NY 10029, USA

* Corresponding author: John A. Martignetti, M.D., Ph.D., Mount Sinai School of Medicine, 1425 Madison Ave, Box 1498, New York, NY 10029, Email: john.martignetti{at}mssm.edu, Tel: (212) 659-6744, Fax: (212) 849-2638

Received December 27, 2006; Revised March 13, 2007; Accepted March 13, 2007

The "vanishing bone" or inherited osteolysis/arthritis syndromes represent a heterogeneous group of skeletal disorders characterized by mineralization defects of affected bones and joints. Differing in anatomical distribution, severity, and associated syndromic features, gene identification in each "vanishing bone" disorder should provide unique insights into genetic/molecular pathways contributing to the overall control of skeletal growth and development. We previously described and then demonstrated that the novel autosomal recessive osteolysis/arthritis syndrome, Multicentric Osteolysis with Arthritis (MOA [MIM #605156]), was caused by inactivating mutations in the MMP2 gene (1). These in vivo results were counterintuitive and unexpected since previous in vitro studies suggested that MMP-2 overexpression and increased activity, not deficiency, would result in the bone and joint features of MOA. The apparent lack of a murine model (2) has hindered studies on disease pathogenesis and, more fundamentally, in addressing the paradox of how functional loss of a single proteolytic enzyme results in an apparent increase in bone loss. Here, we report that Mmp2-/- mice display attenuated features of human MOA including progressive loss of bone mineral density, articular cartilage destruction, and abnormal long bone and craniofacial development. Moreover, these changes are associated with markedly and developmentally-restricted decreases in osteoblast and osteoclast numbers in vivo. Mmp2-/- mice have ~50% fewer osteoblasts and osteoclasts than control littermates at 4 days of life but these differences have nearly resolved by 4 weeks of age. In addition, despite normal cell numbers in vivo at 8 weeks of life, Mmp2-/- bone marrow cells are unable to effectively support osteoblast and osteoclast growth and differentiation in culture. Targeted inhibition of MMP-2 using siRNA in human SaOS2 and murine MC3T3 osteoblast cell lines resulted in decreased cell proliferation rates. Taken together, our findings suggest that MMP-2 plays a direct role in early skeletal development and bone cell growth and proliferation. Thus, Mmp2-/- mice provide a valuable biologic resource for studying the pathophysiologic mechanisms underlying the human disease and defining the in vivo physiologic role of MMP-2.


{dagger} author's current address: Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Toxicol SciHome page
J. M. Hillegass, C. M. Villano, K. R. Cooper, and L. A. White
Glucocorticoids Alter Craniofacial Development and Increase Expression and Activity of Matrix Metalloproteinases in Developing Zebrafish (Danio rerio)
Toxicol. Sci., April 1, 2008; 102(2): 413 - 424.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.